Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model

WEN-HUA YAN, CHANG-YU PAN, JING-TAO DOU, JUN-HUA MENG, BAO-AN WANG and YI-MING MU

Department of Endocrinology, Chinese People’s Liberation Army General Hospital, Beijing 100853, P.R. China

Received February 3, 2015; Accepted April 8, 2016

DOI: 10.3892/etm.2016.3297

Abstract. Angiotensin II type 1 receptor (AT1R) blockers (ARBs) have been shown to reduce the incidence of type 2 diabetes mellitus; however, the underlying molecular mechanism is unknown. Peroxisome proliferator-activated receptor γ (PPARγ) is the central regulator of insulin and glucose metabolism, which improves insulin sensitivity. Whether candesartan cilexetil, as a prodrug of the AT1R blocker candesartan, has PPARγ-activating properties remains to be elucidated. The aim of the present study was to investigate the effects of oral administration of candesartan cilexetil on glucose tolerance and the actions of PPARγ on liver and adipose tissue in the insulin-resistant obese rat induced by high-fat diet. Animals treated with candesartan cilexetil showed an improved glucose tolerance after oral glucose challenge. Whole-body insulin sensitivity was evaluated using the hyperinsulinemic-euglycemic clamp technique. During high-fat feeding in high-fat diet (HF) rats, the glucose infusion rate (GIR) was 52.3% lower than that in normal chow (NC) rats. However, the GIR was significantly enhanced following candesartan cilexetil treatment. Angiotensin II receptor antagonism also resulted in significant increases in PPARγ protein expression in adipose and liver tissue. These results indicate that PPARγ activation by candesartan cilexetil may provide novel therapeutic options in the treatment of patients with metabolic syndrome.

Introduction

Angiotensin II type 1 receptor blockers (ARBs) are widely and safely used as an alternative to angiotensin converting enzyme inhibitors for the treatment of hypertension and hypertension-related cardiovascular diseases without inducing cough (1). In addition to their beneficial effects against hypertension, ARBs have been found to exhibit metabolic actions. In several clinical trials, the incidence of new-onset type 2 diabetes was significantly lower in hypertensive subjects treated with ARBs than in those treated with other hypertensive therapies, which suggests potential antidiabetic effects of angiotensin receptor blockade (2-4). In addition, ARBs have been found to improve insulin sensitivity in a 3T3-L1 cell model of insulin resistance (5). The underlying mechanisms of the insulin-sensitizing/antidiabetic effect of ARBs remain widely unknown.

The peroxisome proliferator-activated receptor-γ (PPARγ) is a clinically validated target for the treatment of insulin resistance and functions as a transcription factor that regulates the gene expression involved in carbohydrate and lipid metabolism, thereby ameliorating type 2 diabetes (6). A study conducted by Benson et al (7) demonstrated that telmisartan exhibited selective PPARγ-modulating activity when tested at concentrations typically achieved in plasma with conventional oral dosing. The other clinically approved ARBs that were tested had little or no effect on PPARγ (7,8), although the oral administration of an extremely high dose of irbesartan (50 mg/kg) was able to cause some activation of the receptor (9).

Therefore, the present study was conducted to investigate whether candesartan cilexetil exerts protective effects on glucose and lipid metabolism and increases PPARγ levels in adipose and liver tissues and thus improves insulin sensitivity in a rat model of diet-induced obesity.

Materials and methods

Correspondence to: Professor Jing-Tao Dou, Department of Endocrinology, Chinese People’s Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, P.R. China
E-mail: jingtadou@sohu.com

Key words: angiotensin II, insulin resistance, peroxisome proliferator-activated receptor γ, angiotensin II type 1 receptor blockers

Chemicals. Affinity-purified rabbit anti-PPARγ polyclonal antibody was purchased from Abcam Inc. (Cambridge, MA, USA; cat. no. ab19481). Human insulin (NovolinR) was from Novo Nordisk (Copenhagen, Denmark). Candesartan cilexetil was provided by Takeda Pharmaceutical Co., Ltd. (Osaka, Japan). Rabbit anti-β-actin polyclonal antibody was from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA; cat. no. sc-1616). Peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) was obtained from Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd. (Beijing, China; cat. no. ZB-2301).
**Animals and treatment.** Male Wistar rats were obtained at 6-7 weeks of age from Vital River Laboratories Co., Ltd. (Beijing, China). The rats were housed two per cage at 22±2°C and a relative humidity of 40-70% under a 12-h light/dark cycle with *ad libitum* access to food and tap water until the start of experiments. Starting at 8-9 weeks of age, the animals were randomly distributed into three groups: Normal chow group (NC group, n=15), high-fat diet group (HF group, n=15) and high-fat diet with daily candesartan cilexetil treatment group (HF + C group, n=15). The normal Chow diet consisted of (as a percentage of total kcal) 17% fat, 63% carbohydrate and 10% protein, and a high-fat diet consisted of 27% fat, 53% carbohydrate and 20% protein. Rats in both the HF group and the HF + C group were initially fed a high-fat diet for 4 weeks, and then respectively received 8 mg/kg/day of either saline (vehicle) or candesartan cilexetil by gavage for 28 consecutive days, during which the high-fat diet was continued.

Blood was drawn from the retro-orbital venous plexus, and blood glucose (BG) was immediately measured with a Bayer Ascensia Breeze™ glucometer (Bayer HealthCare LLC, Mishawaka, IN, USA), after which the blood was collected in a gel tube containing a clotting accelerator and allowed to clot prior to centrifugation for 10 min at 3,000 x g. Subsequently, serum was collected and frozen at -80°C. Serum lipids and lipoproteins were determined using Rat Triglyceride, Cholesterol, Low Density Lipoprotein and High Density Lipoprotein kits (cat. nos. R6635, R6955, R6953 and R6952, respectively; TSZ ELISA, Waltham, MA, USA), according to the manufacturer's protocol. In addition, serum levels of insulin (Insulin RIA kit; Linco Research, Inc., St. Charles, MO, USA) and angiotensin II [ANG II enzyme-linked immunosorbent assay (ELISA) kit; RapidBio, West Hills, CA, USA] were determined. Insulin sensitivity index (ISI), a surrogate index of insulin sensitivity, was calculated as follows: ISI = 1/(FPG x FINS), where FPG is fasting plasma glucose (expressed in mmol/l) and FINS is fasting insulin (expressed in mU/l) (10). All experimental procedures and protocols conformed to guidelines outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996). The present study was approved by the Laboratory Animal Welfare and Ethics Committee of Chinese PLA General Hospital (Beijing, China).

**Oral glucose tolerance tests.** At the end of the 4-week treatment period, the rats were fasted overnight prior to the oral glucose tolerance test (OGTT). Animals underwent feeding with 2 g/kg body weight glucose by gavage. Blood was drawn from a cut at the tip of the tail at 0, 30, 60 and 120 min after the glucose feeding, as previously described (11). Plasma glucose concentrations were determined. The area under the curve (AUC) for glucose during the OGTT was calculated using the trapezoid method (12).

**Hyperinsulinemic-euglycemic clamp analysis.** At the end of the 4-week treatment period, conscious rats received local anesthesia using 2% lidocaine hydrochloride (Abbot Laboratories, North Chicago, IL, USA) on the tail root. The tail artery and vein were catheterized for blood sampling and infusion, respectively. Basic BG and basic insulin were measured. Regular human insulin (Novolin™ R) was infused intravenously at a rate of 0.25 U/kg·h. Hyperinsulinemic-euglycemic clamp analysis was performed as described previously (13). Briefly, blood specimens (30 µl) were obtained from the tail arterial catheter at 5-min intervals for measuring plasma glucose levels by the glucose oxidase method using the Bayer Ascensia Breeze™ glucometer. Based on these values, 10% glucose solution was variably infused to maintain normal glucose levels. A higher glucose infusion rate indicated a higher insulin sensitivity of the peripheral tissue.

**Western blot analysis.** Rats were anesthetized following an overnight fast, and within 10-15 min the abdominal cavity was opened. The perirenal and epididymal adipose tissue, the liver and the heart were removed, snap frozen in liquid nitrogen, weighed and stored at -80°C until processed. Epididymal fat sample was subjected to homogenization as previously described (14). Following centrifugation at 4°C for 20 min at 12,000 x g, the resultant supernatants were used for immunoblotting. Total protein concentration was determined using the bicinchoninic acid method (Pierce BCA Protein Assay kit; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Blots were incubated overnight at 4°C with rabbit anti-PPARγ (1:400 dilution) and rabbit anti-β-actin (1:200 dilution) polyclonal antibodies, followed by incubation for 1 h at room temperature with peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (1:5,000 dilution). The blots were washed and then developed using an ECL Plus immunoblotting detection kit (Applygen Technologies Inc., Beijing, China). The protein bands were visualized by exposure of the membranes to Kodak X-ray film (Kodak, Rochester, NY, USA). Band intensities were scanned using a densitometer (Model GS-710; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and quantified by Quantity One software (Bio-Rad Laboratories, Inc.).

**Immunohistochemistry.** Five-micrometer sections of 4% paraformaldehyde-fixed paraffin-embedded liver tissues were deparaffinized and hydrated. Endogenous peroxidase activity was then blocked with 3% H₂O₂ in phosphate-buffered saline for 10 min, and the tissues were processed for heat-induced antigen retrieval in 0.01 mol/l citrate buffer (pH 6.0) for 10 min. Primary rabbit-anti-PPARγ polyclonal antibody was incubated at a dilution of 1:50-1:100 for 30 min at room temperature before application to tissue sections. A two-step immunohistological detection kit (cat. no. PV-6001; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.), including a goat anti-rabbit IgG-HRP antibody, and a diaminobenzidine (DAB) chromogen (DAB kit; Sigma-Aldrich, St. Louis, MO, USA), were used to visualize specific binding. Five randomly selected high power fields in the centrilobular or periportal areas were examined randomly per section under a light microscope (Olympus CX3; Olympus Corporation, Tokyo, Japan). The number of PPARγ positive hepatocytes was counted in each section. The labeling indices, expressed as the percentage of positive hepatocytes of the total hepatocytes, were calculated.

**Statistical analysis.** Data are expressed as the mean ± standard deviation. Comparisons between groups were performed by one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.
Results

Characteristics of animals studied. The initial body weights were similar in the groups of 15 rats (data not shown). Although the rats in the HF group had significantly higher body weights than those in the NC group from the second week, body weights were lower in the HF + C group than in the HF group from the third week of treatment until the end of the experiment (Fig. 1). The perirenal fat weight, epididymal fat weight and liver weight of the HF + C group were significantly lower than those of the HF group, but higher than those of the NC group (Table I). Although final heart weights and kidney weights of rats in the HF group were slightly, but not significantly, lower than those for rats in the NC group, heart weights were significantly (P<0.05) higher than those for the HF + C group (Table I).

Serum lipid profile and angiotensin II concentration. Although there was no statistically significant difference in serum triglyceride levels among all three groups, animals treated with 8 mg/kg candesartan cilexetil displayed significant reductions in serum cholesterol (1.37±0.39 mmol/l in the HF + C group vs. 2.01±0.26 mmol/l in the HF group; P<0.01) (Table I). Serum angiotensin II levels in the HF group were significantly higher than those in controls (P<0.05); furthermore, the increase in angiotensin II levels in the HF + C group was significantly more pronounced than that in the HF group (P<0.05) due to angiotensin II type 1 (AT1) receptor blockade (Table I).

Glucose and insulin concentrations. Fasting blood glucose levels were comparable in the NC and HF groups. Candesartan cilexetil showed a tendency to lower the blood glucose levels in the high-fat-fed rats, but this effect did not reach statistical significance (P>0.05; Table I). The fasting insulin levels in the HF group were significantly higher compared with those in the NC group (P<0.05; Table I). However, animals receiving candesartan cilexetil displayed significant reductions in insulin levels (36%; P<0.05) compared with those in the HF group. As an indirect marker of peripheral insulin action, the ISI was calculated for each animal. As shown in Table I, the ISI of rats in the HF group was substantially lower compared with that of rats in the NC group, but the ISI of rats in the HF + C group

| Characteristic | NC group | HF group | HF + C group |
|----------------|----------|----------|--------------|
| Body weight, g | 461.33±36.48 | 518.40±28.30a | 478.33±34.79b |
| Perirenal fat weight, g | 13.54±3.21 | 26.89±4.81a | 20.50±4.09ac |
| Epididymal fat weight, g | 7.64±1.72 | 11.50±1.95a | 9.61±1.83ab |
| Heart weight, g | 1.34±0.07 | 1.29±0.13 | 1.09±0.11ab |
| Liver weight, g | 13.04±1.63 | 17.86±1.76a | 15.72±1.70ac |
| Kidney weight, g | 2.46±0.24 | 2.28±0.17 | 2.25±0.18 |
| Triglyceride, mmol/l | 1.82±0.67 | 1.27±0.24 | 1.30±0.37 |
| Total cholesterol, mmol/l | 1.62±0.54 | 2.01±0.26c | 1.37±0.39b |
| Low-density lipoprotein cholesterol, mmol/l | 0.07±0.03 | 0.72±0.15a | 0.62±0.23a |
| High-density lipoprotein cholesterol, mmol/l | 0.75±0.13 | 0.6±0.06a | 0.68±0.11 |
| Serum angiotensin II, pg/ml | 43.73±5.63 | 51.88±9.70d | 60.82±10.76bd |
| Fasting blood glucose, mmol/l | 6.18±0.73 | 6.38±0.66 | 5.76±0.92 |
| Fasting serum insulin, mU/l | 1.57±0.98 | 4.76±2.75d | 3.03±1.37cd |
| Insulin sensitivity index, x10⁻³ | 98.76±16.72 | 29.37±8.95d | 57.93±11.83cd |
| Hyperinsulinemic euglycemic clamp study, glucose infusion rate, mg/kg/min | 28.3±5.4 | 13.5±3.9a | 22.4±5.1b |

Rat groups were as follows: NC, normal chow; HF, high-fat diet; HF + C, high-fat diet with daily candesartan cilexetil treatment. Data are presented as the mean ± standard deviation (n=15 per group). *P<0.01 vs. the NC group; †P<0.01 vs. the HF group; ‡P<0.05 vs. the HF group; §P<0.05 vs. the NC group.

Figure 1. Changes in the body weight of rats. Rat groups were as follows: NC, normal chow; HF, high-fat diet; HF + C, high-fat diet with daily candesartan cilexetil treatment. Data are presented as the mean ± standard deviation (n=15).
YAN et al: CANDESARTAN ACTIVATES PPARγ

was significantly higher compared with that of the animals in the HF group (P<0.05).

Glucose response during an OGTT in the candesartan cilexetil treatment group is shown in Fig. 2A. Compared with the HF group, treatment with 8 mg/kg candesartan cilexetil did not cause significantly lower glucose values at 0 min, whereas treatment resulted in lower glucose values (18, 7 and 13% lower, respectively; all P<0.05) at the 30, 90 and 120 min time points. The AUC values for glucose are presented in Fig. 2B; a reduction in this value reflects an increase in insulin sensitivity (15). A significantly higher AUC for glucose was calculated during the OGTT for the rats in the HF group compared with the NC group (14.05±2.05 vs. 11.96±1.35 mmol·h/l; P<0.05). Animals in the HF + C group had a lower glucose AUC than those in the HF group (12.44±2.95 vs. 14.05±2.05 mmol·h/l; P<0.05) during the OGTT.

Whole-body insulin sensitivity was evaluated using the hyperinsulinemic-euglycemic clamp technique (Table I). During high-fat feeding in the HF group, the glucose infusion rate (GIR) was 52.3% lower than that in the NC group. However, the GIR was significantly enhanced following candesartan cilexetil treatment (by 65.9%; P<0.01).

**PPARγ expression in the epididymal adipose tissue and liver tissue.** To identify the potential activation of PPARγ brought about by candesartan cilexetil, protein levels of PPARγ in epididymal adipose tissue were assessed by western blotting. High-fat feeding significantly reduced the amount of PPARγ in the adipose tissue compared with that in HF rats treated with saline. Candesartan cilexetil treatment together with a high-fat diet caused a significant increase in PPARγ expression compared with that in rats fed a high-fat diet and treated with saline (Figs. 3 and 4).

Subsequent immunohistochemical analysis of the liver tissue is shown in Fig. 5. Periportal and centrilobular hepatocytes exhibited low positivity for PPARγ in the livers of rats in the HF group. However, levels of PPARγ expression were increased significantly (P<0.05) in the livers of rats treated with candesartan cilexetil (Figs. 5 and 6).

**Discussion**

In order to study the influence of the renin-angiotensin system on adipose and liver tissue, diet-induced obese rats were treated with long-term administration of candesartan cilexetil. Absorbed candesartan cilexetil is completely

Figure 2. Effect of candesartan cilexetil on (A) glucose responses during the OGTT and (B) glucose AUC. Compared with the HF group, candesartan treatment resulted in lower glucose values and decreased AUC values implying improved insulin resistance. Rat groups were as follows: NC, normal chow; HF, high-fat diet; HF + C, high-fat diet with daily candesartan cilexetil treatment. Data are presented as the mean ± standard deviation (n=15). *P<0.05 vs. the NC group; †P<0.05 vs. the HF group. OGTT, oral glucose tolerance test; AUC, area under the curve.

Figure 3. Western blots showing the effect of candesartan cilexetil on the protein expression of PPARγ in white adipose tissue. Candesartan cilexetil treatment together with high-fat diet induced a clear increase in PPARγ compared with that in HF rats treated with saline. Rat groups were as follows: NC, normal chow; HF, high-fat diet; HF + C, high-fat diet with daily candesartan cilexetil treatment. PPARγ, peroxisome proliferator-activated receptor-γ.

Figure 4. Quantification of the amount of PPARγ protein in white adipose tissue. Rats groups were as follows: NC, normal chow; HF, high-fat diet; HF + C, high-fat diet with daily candesartan cilexetil treatment. PPARγ, peroxisome proliferator-activated receptor-γ. Data are presented as the mean ± standard deviation (n=5). *P<0.05 vs. the HF group.

Figure 5. Whole-body insulin sensitivity was evaluated using the hyperinsulinemic-euglycemic clamp technique (Table I). During high-fat feeding in the HF group, the glucose infusion rate (GIR) was 52.3% lower than that in the NC group. However, the GIR was significantly enhanced following candesartan cilexetil treatment (by 65.9%; P<0.01).

**PPARγ expression in the epididymal adipose tissue and liver tissue.** To identify the potential activation of PPARγ brought about by candesartan cilexetil, protein levels of PPARγ in epididymal adipose tissue were assessed by western blotting. High-fat feeding significantly reduced the amount of PPARγ in the adipose tissue compared with that in rats of the NC group. Candesartan cilexetil treatment together with a high-fat diet caused a significant increase in PPARγ expression compared with that in rats fed a high-fat diet and treated with saline (Figs. 3 and 4).

**Discussion**

In order to study the influence of the renin-angiotensin system on adipose and liver tissue, diet-induced obese rats were treated with long-term administration of candesartan cilexetil. Absorbed candesartan cilexetil is completely

Figure 3. Western blots showing the effect of candesartan cilexetil on the protein expression of PPARγ in white adipose tissue. Candesartan cilexetil treatment together with high-fat diet induced a clear increase in PPARγ compared with that in HF rats treated with saline. Rat groups were as follows: NC, normal chow; HF, high-fat diet; HF + C, high-fat diet with daily candesartan cilexetil treatment. PPARγ, peroxisome proliferator-activated receptor-γ.

Figure 4. Quantification of the amount of PPARγ protein in white adipose tissue. Rats groups were as follows: NC, normal chow; HF, high-fat diet; HF + C, high-fat diet with daily candesartan cilexetil treatment. PPARγ, peroxisome proliferator-activated receptor-γ. Data are presented as the mean ± standard deviation (n=5). *P<0.05 vs. the HF group.
metabolized to candesartan. The absolute bioavailability is relatively poor at 15% (candesartan cilexetil tablets) to 40% (candesartan cilexetil solution) (16), and the dose administered (8 mg/kg/day) was chosen because it had been demonstrated to be effective in a previous insulin-resistant obese rat model without any overt signs of toxicity (17). In the present study, it was demonstrated that high-fat feeding of male Wistar rats caused insulin resistance, increased plasma total cholesterol, low-density lipoprotein cholesterol, body weight and adiposity. Treatment with candesartan cilexetil for 4 weeks improved insulin sensitivity, decreased plasma lipid levels and adiposity. The induction of PPARγ activity demonstrates new pleiotropic actions of candesartan cilexetil, providing a potential mechanism for its insulin-sensitizing effects. Clinical observation of a reduction in the development of diabetes mellitus with candesartan cilexetil is supported by the Candesartan in Heart-Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Preserved trial (18), wherein the incidence of new-onset type 2 diabetes was significantly lower in subjects given candesartan cilexetil than in those given matching placebo, implicating an antidiabetic action of candesartan cilexetil. However, notably, in other trials involving candesartan cilexetil, the CHARM Alternative (19), the CHARM Added (20), and the Study on Cognition and Prognosis in the Elderly (SCOPE) (21), there was no benefit of candesartan cilexetil over placebo in the prevention of incident diabetes. Candesartan cilexetil also failed to show any effect on glucose, insulin or lipid levels in both the Candesartan Role in Obesity and on Sympathetic System (CROSS) (22) and Antihypertensive Treatment and Lipid Profile in a North Sweden Efficacy Evaluation (ALPINE) (23).

As previously reported with AT1 receptor (AT1R) blocker therapy (24), the data obtained in the present study showed a marked postprandial 2 h glucose level reduction and higher GIR in rats in the HF + C group treated for 21 days with candesartan cilexetil. Fasting glucose levels were similar among the three groups, whereas fasting insulin levels in rats fed a high-fat diet were significantly higher than those in the chow-fed controls. The observation of normoglycemia with hyperinsulinemia indicates that the rats fed a high-fat diet were insulin resistant. Increased glucose levels and AUC of glucose were also observed following glucose loading in fat-fed rats. Despite high insulin levels, the AUC of glucose in the HF group was greater than that of HF + C group. However, the insulin levels of rats treated with candesartan cilexetil were found to be significantly lower compared with those of the HF control rats. These results indicate that although candesartan cilexetil does not affect insulin in normal conditions, under conditions of hyperinsulinemia, it increases insulin sensitivity for effective glucose disposal.

PPARs are ligand-activated transcription factors that have a number of pleiotropic effects (25). The γ-subtype of the receptor (PPARγ) plays an important role in carbohydrate and lipid metabolism and is a therapeutic target in the treatment of insulin resistance, diabetes and metabolic syndrome (26). PPARγ is mainly expressed in adipocytes as well as hepatocytes and considered to be a key regulator of adipocyte differentiation (27). Thiazolidinediones typically function as full agonists of PPARγ and improve insulin signaling and insulin sensitivity (28). Some ARBs such as telmisartan and irbesartan, are partial agonists of PPARγ and are able to induce its activity and adipocyte differentiation independent of their blocking properties. However, other ARBs have failed to show any effects on PPARγ activity or adipogenesis (29).

A major finding in the present study is that candesartan cilexetil has PPARγ-activating properties. The 8 mg/kg/day dose of candesartan cilexetil in rats is approximately twice the maximum recommended daily human dose of 32 mg on a mg/m² basis (this comparison assumes a human body weight of 50 kg). That the dosage required in obese rats was much higher than that recommended in humans may be due to inter-species differences or to the fact that obese rats have not only glucose and lipid metabolic disorders but also insulin resistance. The mechanism
by which candesartan cilexetil activates PPARγ remains to be precisely defined. However, its relatively high volume of distribution and lipophilicity, which have sufficiently high penetration rates to gain access to the PPARγ-retinoid X receptor complex within the cell nucleus, may be relevant. Once activated, the complex influences the expression of the key target gene glucose transporter-4 (GLUT-4) and increases glucose delivery to skeletal muscle by improving insulin sensitivity (30). Consistent with the latter hypothesis, we have observed that candesartan cilexetil shows other properties of a PPARγ activator, which can induce small increases in GLUT-4 protein expression in the skeletal muscle of obesity-associated rats (unpublished data). In addition, PPARγ-activating candesartan cilexetil promotes adipocyte differentiation, resulting in the redistribution of lipids from ectopic distribution to adipose tissue and may increase adiponectin levels in humans (31), thereby contributing to the weight loss and adiposity reduction of rats.

Obesity is one of the most common causes of insulin resistance. Adipose tissue, particularly in the visceral compartment, secretes various bioactive molecules that may directly contribute to the development of obesity-related diseases. It is acknowledged that adipose tissue is a complex and highly active metabolic and endocrine organ (32), producing proteins such as leptin, adiponectin and resistin (33). Several peptides of the renin-angiotensin system (34) are also produced in adipose tissue. Angiotensin II is a main final effector molecule of the renin-angiotensin system. The present study confirms that serum angiotensin II levels are elevated in diet-induced obese rats. This finding is consistent with earlier observations that circulating levels of angiotensinogen, renin and angiotensin II were increased in obese individuals (35). Systemic and local angiotensin II has been shown to inhibit substrate delivery and cross-talk between angiotensin and insulin receptor signaling pathways, which can be restored by AT1R antagonism (36). Beneficial effects of ARBs on impaired insulin signaling may represent an additional molecular mechanism for insulin sensitizing actions. Blockade of AT1 receptors leads to compensatory increases in angiotensin II levels and the subsequent increased activation of AT2 receptors (37). The AT2 receptor is now recognized as the counter-regulator of the AT1 receptor, exerting mostly beneficial actions (38). It has been reported that angiotensin II stimulation can decrease the expression of PPARγ in cardiac myofibroblasts (39), while PPARγ causes a downregulation of AT1R gene expression via a PPARγ-dependent mechanism in vascular smooth muscle cells (40). Therefore, PPARγ may also play a role in the regulation of angiotensin II action. Candesartan cilexetil, by virtue of its ability to block AT1Rs and to activate PPARγ, may not only inhibit angiotensin II-mediated pathways of insulin resistance, but also stimulate PPARγ pathways that help prevent resistance.

There are several limitations of the present study. First, the study did not demonstrate that candesartan cilexetil stimulates PPARγ activation independent of AT1R blocking actions in the absence of AT1R. Second, the effects of different ARBs with PPARγ-activating properties were not compared. The superiority of candesartan cilexetil for the enhancement of insulin sensitivity in association with improvement of insulin resistance requires further assessment.

In summary, the present study has demonstrated that long-term administration of candesartan cilexetil, a specific ARB, to insulin-resistant obese rats elicited a great improvement of whole-body insulin sensitivity, at least in part because of PPARγ activation. This angiotensin II receptor antagonism also resulted in significant increases in PPARγ protein expression in adipose and liver tissue. PPARγ activation by candesartan cilexetil may provide novel therapeutic options in the treatment of patients with metabolic syndrome.

Acknowledgements

This study has benefited from research funding from National Natural Science Foundation of China (no. 30671095).

References

1. Neel JM: Choosing among renin-angiotensin system blockers for the management of hypertension: From pharmacology to clinical efficacy. Curr Med Res Opin 26: 213-222, 2010.
2. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beegers G, de Faire U, Fyhquist F, Ibsen H, Kristiansson K, Leinderaulle-Pedersen G; LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003, 2002.
3. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hutt T, Laragh J, Melzner GT, Mitchell L, et al.; VALUE Study Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363: 2022-2031, 2004.
4. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beegers G, de Faire U, Fyhquist F; LIFE Study Group: RAS of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20: 1879-1886, 2002.
5. Claessen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemens M, Krikov M, Thöne-Reinecke C, Unger T and Kintschner U; PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46: 137-143, 2005.
6. Higgins LS and Depaoli AM: Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 91: 2675-2728, 2010.
7. Benson SC, Pershad singh HA, Ho CI, Chittiboyina A, Desai P, P ravenece M, Qi N, Wang J, Avery MA and Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002, 2004.
8. Schupp M, Janke J, Claessen R, Unger T and Kintschner U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057, 2004.
9. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK and Krekker M; Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884-890, 2001.
10. Li GW and Pan XR: A new insulin-sensitivity index for the population-based study. Zhonghua Nei Ke Za Zhi 32: 656-660, 1993 (In Chinese).
11. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, Bobby Z and Selvaraj N; Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr 99: 806-812, 2008.
12. Allison DB, Paultre F, Maggio C, Mezzitis N and Pi-Sunyer FX; The use of areas under curves in diabetes research. Diabetes Care 18: 245-250, 1995.
13. Cheung A and Breyer-Ash M; Modified method for the performance of glucose insulin clamp studies in conscious rats. J Pharmacol Toxicol Methods 31: 215-220, 1994.
14. Kump DS and Booth FW; Sustained rise in triacylglycerol synthesis and increased epididymal fat mass when rats cease voluntary wheel running. J Physiol 565: 911-925, 2005.
15. Matsuda M and DeFronzo RA; Insulin sensitivity indices obtained from oral glucose tolerance testing; Comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
16. Burnier M and Brunner HR; Angiotensin II receptor antagonists. Lancet 355: 637-645, 2000.
17. Tuncer I, Ozbek H, Ugras S and Bayram I: Anti-ibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol 55: 159-166, 2003.

18. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B and Ostergren J; CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved trial. Lancet 362: 777-781, 2003.

19. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA and Swedberg K; CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: The CHARM-Alternative trial. Lancet 362: 772-776, 2003.

20. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S and Pfeffer MA; CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362: 767-771, 2003.

21. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P and Zanchetti A; SCOPE Study Group: The Study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 21: 875-886, 2003.

22. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, Facchini A and Mancia G; CROSS Study: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 21: 1761-1769, 2003.

23. Lindholm LH, Persson M, Alauovic P, Carlberg B, Svensson A and Samuelsson O: Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy evaluation (ALPINE study). J Hypertens 21: 1563-1574, 2003.

24. Kinnick TR, Youngblood EB, O'Keefe MP, Saengsirisuwon V, Teachey MK and Henriksen EJ: Modulation of insulin resistance and hypertension by voluntary exercise training in the TG(mREN2)27 rat. J Appl Physiol (1985) 93: 805-812; discussion 797, 2002.

25. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahtilly S, et al: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741, 2006.

26. Balakumar P, Rose M and Singh M: PPAR ligands: Are they potential agents for cardiovascular disorders? Pharmacology 80: 1-10, 2007.

27. Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature 405: 421-424, 2000.

28. Spiegelman BM: PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998.

29. Kurtz TW: Treating the metabolic syndrome: Telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42 (Suppl 1): S9-S16, 2005.

30. Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjöquist PO and Abrahamsson T: Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 33: 1406-1413, 1999.

31. Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y and Shin EK: Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 108: 96-100, 2006.

32. Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ and Burrell MA: The adipocyte: A model for integration of endothocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280: E827-E847, 2001.

33. Banerjee RR and Lazar MA: Resistin: Molecular history and prognosis. J Mol Med (Berl) 81: 218-226, 2003.

34. Goossens GH, Blaak EE and van Baak MA: Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 4: 43-55, 2003.

35. Engeli S, Böhne J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC and Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45: 356-362, 2005.

36. Motley ED, Eguchi K, Gardner C, Hicks AL, Reynolds CM, Frank GD, Mifune M, Obba M and Eguchi S: Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 41: 775-780, 2003.

37. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Gishahriu K and Shimamoto K: Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22: 1977-1982, 2004.

38. de Gasparo M, Catt KJ, Inagami T, Wright JW and Unger T: International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472, 2000.

39. Hao GH, Niu XL, Gao DF, Wei J and Wang NP: Agonists at PPAR-gamma suppress angiotensin II-induced production of plasmogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 153: 1409-1419, 2008.

40. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kado M, Sato K, Taniyama Y and Ito S: Transcriptional suppression of type I angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142: 3125-3134, 2001.